MRNA:NSD-Moderna Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 282.35

Change

+17.02 (+6.41)%

Market Cap

USD 122.24B

Volume

0.01B

Avg Analyst Target

USD 338.33 (+19.83%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Moderna Inc (MRNA) Stock Analysis:
Based on the Moderna Inc stock forecasts from 12 analysts, the average analyst target price for Moderna Inc is USD 338.33 over the next 12 months. Moderna Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Moderna Inc is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Moderna Inc’s stock price was USD 282.35. Moderna Inc’s stock price has changed by -70.08 % over the past week, +45.36 % over the past month and +66.23 % over the last year.

About

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clini ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BNTX BioNTech SE

+22.86 (+8.17%)

USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
TECH Bio-Techne Corporation

+4.72 (+1.01%)

USD17.92B 107.96 64.40

ETFs Containing MRNA

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 11.18 % 0.35 %

+7.81 (+4.29%)

USD0.57B
IPO Renaissance IPO ETF 8.74 % 0.60 %

+2.58 (+4.53%)

USD0.63B
BTEE:LSE iShares Nasdaq US Biotech.. 8.69 % 0.35 %

+0.15 (+2.35%)

USD0.04B
BTEK:LSE iShares IV Public Limited.. 8.69 % 0.35 %

+0.21 (+4.37%)

USD0.48B
BTEC:LSE iShares Nasdaq US Biotech.. 8.69 % 0.35 %

+0.28 (+4.38%)

USD0.48B
IBB iShares Biotechnology ETF 8.45 % 0.45 %

+5.70 (+3.92%)

USD10.94B
2B70:XETRA iShares Nasdaq US Biotech.. 7.43 % 0.35 %

+0.29 (+5.03%)

USD0.46B
BIB ProShares Ultra Nasdaq Bi.. 6.96 % 0.95 %

+5.76 (+7.74%)

USD0.27B
IDNA iShares Genomics Immunolo.. 6.78 % 0.47 %

+2.40 (+5.55%)

USD0.35B
IBBQ Invesco Nasdaq Biotechnol.. 6.68 % 0.19 %

+0.97 (+4.26%)

N/A
ZGEN:CA BMO MSCI Genomic Innovati.. 6.46 % 0.00 %

+1.30 (+4.85%)

N/A
AMOM QRAFT AI-Enhanced U.S. La.. 5.14 % 0.75 %

+1.48 (+4.24%)

USD0.03B
GERM ETF Managers Trust - ETFM.. 5.00 % 0.68 %

+2.08 (+5.87%)

N/A
ZINN:CA BMO MSCI Innovation Index.. 4.43 % 0.00 %

+0.82 (+2.76%)

N/A
FBT First Trust NYSE Arca Bio.. 3.95 % 0.55 %

+4.57 (+2.99%)

USD1.93B
BBP ETFis Series Trust I - Vi.. 3.73 % 0.79 %

+1.78 (+3.89%)

USD0.03B
HWF:CA Middlefield Healthcare & .. 3.52 % 1.45 %

+0.06 (+0.46%)

USD0.05B
LS:CA Middlefield Healthcare & .. 3.47 % 1.31 %

+0.05 (+0.44%)

USD0.08B
SPMO Invesco S&P 500 Momentum .. 3.24 % 0.13 %

+1.47 (+2.32%)

USD0.09B
BBIG:CA Horizons Global BBIG Tech.. 3.14 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 3.09 % 0.79 %

N/A

N/A
FHH:CA First Trust AlphaDEX U.S... 3.09 % 0.77 %

N/A

USD0.02B
IUMO:LSE iShares Edge MSCI USA Mom.. 2.82 % 0.20 %

+0.41 (+3.35%)

USD1.98B
IUMF:LSE IShares Edge MSCI USA Mom.. 2.82 % 0.20 %

+34.75 (+3.81%)

USD0.70B
IUMD:LSE iShares Edge MSCI USA Mom.. 2.82 % 0.20 %

-0.05 (-0.60%)

USD0.01B
TECB iShares U.S. Tech Breakth.. 2.75 % 0.40 %

+1.46 (+3.56%)

N/A
ZUH:CA BMO Equal Weight US Healt.. 2.07 % 0.39 %

+1.90 (+2.41%)

USD0.50B
MWD:CA Mackenzie Maximum Diversi.. 1.94 % 0.55 %

+0.08 (+0.28%)

USD0.45B
FLAG FLAG-Forensic Accounting .. 1.92 % 1.44 %

N/A

USD4.83M
MUS:CA Mackenzie Maximum Diversi.. 1.65 % 0.50 %

+0.37 (+1.04%)

USD0.20B
MXDU Nationwide Maximum Divers.. 1.37 % 0.34 %

+0.73 (+1.84%)

USD0.12B
QQEQ:CA Invesco NASDAQ 100 Equal .. 1.15 % 0.00 %

N/A

N/A
SFY Tidal ETF Trust - SoFi Se.. 1.08 % 0.00 %

+0.38 (+2.24%)

USD0.24B
ULVM VictoryShares USAA MSCI U.. 1.07 % 0.20 %

+1.26 (+1.85%)

USD0.44B
FTGU:XETRA First Trust Global Funds .. 0.59 % 0.75 %

+1.60 (+2.55%)

USD0.06B
IUSS Invesco RAFI Strategic US.. 0.46 % 0.23 %

+0.68 (+1.77%)

USD0.04B
XRSM:F Xtrackers (IE) Public Lim.. 0.45 % 0.35 %

+0.85 (+2.51%)

USD0.11B
SIZE iShares MSCI USA Size Fac.. 0.35 % 0.15 %

+2.59 (+1.95%)

USD0.66B
EUSA iShares MSCI USA Equal We.. 0.24 % 0.15 %

+1.61 (+1.86%)

USD0.45B
QBTL:CA AGFiQ US Market Neutral A.. 0.21 % 0.55 %

-0.18 (-1.06%)

USD0.16B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

+0.72 (+1.63%)

USD0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 170.27% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 170.27% 96% A 97% A+
Trailing 12 Months  
Capital Gain 66.23% 90% A- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.23% 90% A- 88% B+
Trailing 5 Years  
Capital Gain N/A 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain 769.70% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 769.70% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 983.83% 3% F 2% F
Risk Adjusted Return 78.24% 95% A 87% B+
Market Capitalization 122.24B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.38 34% F 46% F
Price/Book Ratio 12.07 8% F 9% F
Price / Cash Flow Ratio 60.31 2% F 7% F
EV/EBITDA 14.64 25% F 46% F
Management Effectiveness  
Return on Equity 109.61% 100% A+ 99% A+
Return on Invested Capital -40.99% 58% F 20% F
Return on Assets 37.20% 100% A+ 100% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.28 80% B- 71% C-
Short Percent 4.90% 43% F 33% F
Beta 1.31 48% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector